HER2-Positive Breast Cancer

Congratulations to Dr Chawla who has recently written a case report entitled ‘Annular atrophic lichen planus induced by anti-HER2 antibodies’. This has been published in the Australasian Journal of Dermatology.

Monoclonal inhibitors Pertuzumab and Trastuzumab inhibit human epidermal growth factors receptor 2 (HER-2). These are used to treat HER-2 positive breast cancer. Our case highlights a rare variant of a lichenoid drug eruption in a 35 year old female. Recognising rare potential side effects can ensure patients do not require treatment interruption.

Read the article by visiting here.

To arrange an appointment with Dr Kara Heelan, at Chelsea Outpatient Centre or Sydney Street Outpatients & Diagnostic Centre call us on 02034944024.